# of Displayed Technologies: 10 / 33


Categories

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Schultz, Teri

Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
  • College: College of Medicine (COM)
  • Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
  • Licensing Officer: Schultz, Teri

Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes. The Need Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells. The Need Current therapies…
  • College: College of Medicine (COM)
  • Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
  • Licensing Officer: Schultz, Teri

Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
  • College: College of Medicine (COM)
  • Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
  • Licensing Officer: Schultz, Teri

Decision Support Tool for Prevention of Failure to Rescue Events
TS-064718 — A clinical decision support tool for minimizing failure to rescue events at hospitals.
Failure to rescue (FTR) is a serious issue in patient safety and healthcare quality for hospitalized patients. The term implies that rescue is possible, and death is, therefore, a failure. On any given day across the country, two-thirds of deaths in hospitals could be judged as preventable. In 2005,…
  • College: OSU Wexner Medical Center
  • Inventors: Garvey, Paula; Justice, Stephanie
  • Licensing Officer: Schultz, Teri

Innovative Solutions for Acute Myeloid Leukemia: The Role of EGFL7
TS-064071 — EGFL7-centric technology for diagnosis, prognosis, and therapeutic strategies for hematologic malignancies.
The complex genetic landscape of Acute Myeloid Leukemia (AML), marked by chromosomal alterations and gene mutations, necessitates innovative approaches. The Need AML poses a significant challenge in the realm of hematologic malignancies, demanding both prognostic markers and novel treatments. Curr…
  • College: College of Medicine (COM)
  • Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
  • Licensing Officer: Schultz, Teri

Skin Healing Technology: Dermal Substitutes and Engineered Skin with Rete Ridges
TS-064046 — Dermal substitute with engineered rete ridges improves epidermal-dermal communication and enhances burn wound treatment.
Massive burn injuries present a critical challenge in wound healing and prevention of infection. Current treatment methods are susceptible to blistering and other problems that can reduce engraftment. The Need Cultured epithelial autografts (CEAs) are a vital component in treating large burns, but…
  • College: College of Engineering (COE)
  • Inventors: Powell, Heather; Bailey, John; Blackstone, Britani "Niki"
  • Licensing Officer: Schultz, Teri

Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings. The Need The rise of these resilient multi-drug resistant bacteria has …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Schultz, Teri

Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
  • College: College of Engineering (COE)
  • Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
  • Licensing Officer: Schultz, Teri

Show More Technologies

Loading icon